HPGC Renmintongtai Pharmaceutical Corp (600829) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for HPGC Renmintongtai Pharmaceutical Corp (SSE:600829), currently being evaluated. In 2025, HPGC Renmintongtai Pharmaceutical Corp generated $10.38 Billion in revenue and $282.82 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for HPGC Renmintongtai Pharmaceutical Corp is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $10.38 Billion
- Free Cash Flow (2025): $282.82 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.